Hollings Cancer Center researchers have identified one reason why triple-negative breast cancer becomes resistant to ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

A team of MUSC Hollings Cancer Center researchers has discovered one way in which triple-negative breast cancer (TNBC) cells become resistant to immunotherapy and have tested a two-pronged treatment ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer center for the Mountain West, have made a significant breakthrough in ...

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ ... a phase 2 study that enrolled 43 patients with stage I-III triple-negative breast cancer (TNBC). Patients in the study underwent short-term ...

The presentation was entitled, The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC), presenting the current ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ ... updated ivonescimab data in advanced triple-negative breast cancer (TNBC), recurrent / metastatic head and neck squamous cell carcinoma ...

Two Oral Presentations Featured Updated Ivonescimab Data from Phase II Studies in CRC and TNBC in Addition to Poster Presentation on HNSCC Encouraging Phase II Data Supports the Continuing Expansion ...